Chemotherapy Must Haves For Women Market Report: Sales Volume, Market Share, Leading Brands & Market Trends

Pedialyte is the best-performing chemotherapy must haves for women brand in July 2026, moving 10,000 units across 1 ASIN for 16.9% of Top 10 volume. ACT follows with 10,000 units (16.9%), ahead of myhalos on 10,000 units (16.9%).

Volume is spread across 10 brands, with the top three holding 50.8% between them. No single label controls the shelf, which usually leaves room for a well-differentiated listing to take share without outspending an incumbent. Average selling prices among the leaders run from $6.54 to $17.48, which frames the price band a competing listing has to justify.

Based on July 2026 data, this shortlist surfaces the two kinds of ASIN worth keeping an eye on — the ones that just broke into the Top 10, and the ones growing fastest month over month. Specifically, one ASIN forced its way in: B0B4F45C6Y booked 2K units at $9.99, with ▲ 100.0% MoM change. On the growth side, B09F34DXLK leads positive momentum with ▲ 200.0% MoM growth on 300 units, with B0DJBGMMCP close behind at ▲ 100.0% MoM on 200 units.

The two signals carry different weight. A fresh entrant means share has already changed hands — an incumbent gave up its place to make room, so any competitive set drawn up a month ago is now out of date. A steep growth rate works as the earlier warning: it marks demand that is still compounding, usually a month or two before the ranking catches up to it.